This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brady, H. J. Articles by Dzierzak, E. A. Search for Related Content PubMed PubMed Citation Articles by Brady, H. J. Articles by Dzierzak, E. A.

 Previous Article  |  Next Article 

J. Virol., Dec 1995, 7622-7629, Vol 69, No. 12
Copyright © 1995, American Society for Microbiology

Altered cytokine expression in T lymphocytes from human immunodeficiency virus Tat transgenic mice

HJ Brady, DJ Abraham, DJ Pennington, CG Miles, S Jenkins and EA Dzierzak
Laboratory of Gene Structure and Expression, National Institute for Medical Research, Mill Hill, London, United Kingdom.

Examination of the interaction between human immunodeficiency virus (HIV) regulatory gene products and the host immune system is fundamental to understanding the pathogenesis of HIV and could reveal possible targets for therapeutic intervention in the treatment of AIDS. The HIV Tat gene is a potential candidate for this type of strategy. Transgenic mice can be used to investigate the in vivo effects of Tat on the developing and dynamic immune system and on cellular gene expression. Thus, we have generated transgenic mice that harbor the HIV type 1 Tat gene under the transcriptional control of the human CD2 gene regulatory elements. This expression cassette results in high-level, tissue-specific transcription of the transgene within the T-cell compartment. In this report, we demonstrate the effects of Tat on the in vivo immune system. CD2-Tat transgenic mice show no signs of aberrant thymic development and have normal levels of T-cell subsets in the thymus and peripheral lymphoid organs. However, activated T cells from transgenic mice contain increased levels of tumor necrosis factor beta mRNA as well as biologically active tumor necrosis factor protein and express elevated levels of transforming growth factor beta and interleukin-4 receptor mRNA. These increased cytokine levels do not appear to alter mitogen- or antigen-stimulated responses or induce the formation of dermal lesions in ageing mice. Such investigations should provide insight into the combination of host immune factors mediating pathogenesis in HIV infection.

This article has been cited by other articles:

• Rahim, M. M. A., Chrobak, P., Hu, C., Hanna, Z., Jolicoeur, P. (2009). Adult AIDS-Like Disease in a Novel Inducible Human Immunodeficiency Virus Type 1 Nef Transgenic Mouse Model: CD4+ T-Cell Activation Is Nef Dependent and Can Occur in the Absence of Lymphophenia. J. Virol. 83: 11830-11846 [Abstract] [Full Text]  
• Raidel, S. M., Haase, C., Jansen, N. R., Russ, R. B., Sutliff, R. L., Velsor, L. W., Day, B. J., Hoit, B. D., Samarel, A. M., Lewis, W. (2002). Targeted myocardial transgenic expression of HIV Tat causes cardiomyopathy and mitochondrial damage. Am. J. Physiol. Heart Circ. Physiol. 282: H1672-H1678 [Abstract] [Full Text]  
• Ikuta, K., Suzuki, S., Horikoshi, H., Mukai, T., Luftig, R. B. (2000). Positive and Negative Aspects of the Human Immunodeficiency Virus Protease: Development of Inhibitors versus Its Role in AIDS Pathogenesis. Microbiol. Mol. Biol. Rev. 64: 725-745 [Abstract] [Full Text]  
• Prakash, O., Tang, Z.-Y., He, Y.-e, Ali, M. S., Coleman, R., Gill, J., Farr, G., Samaniego, F. (2000). Human Kaposi's Sarcoma Cell-Mediated Tumorigenesis in Human Immunodeficiency Type 1 Tat-Expressing Transgenic Mice. JNCI J Natl Cancer Inst 92: 721-728 [Abstract] [Full Text]  
• Cohen, S. S., Li, C., Ding, L., Cao, Y., Pardee, A. B., Shevach, E. M., Cohen, D. I. (1999). Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge. Proc. Natl. Acad. Sci. USA 96: 10842-10847 [Abstract] [Full Text]  
• Moses, A., Nelson, J., Bagby, G. C. Jr (1998). The Influence of Human Immunodeficiency Virus-1 on Hematopoiesis. Blood 91: 1479-1495 [Full Text]  
• Bour, S., Perrin, C., Akari, H., Strebel, K. (2001). The Human Immunodeficiency Virus Type 1 Vpu Protein Inhibits NF-kappa B Activation by Interfering with beta TrCP-mediated Degradation of Ikappa B. J. Biol. Chem. 276: 15920-15928 [Abstract] [Full Text]